Will Ashworth

Will Ashworth

Expertise: Public and private companies, Portfolio construction

About Will:
Will Ashworth has written about investments full-time since 2008. He loves investing and is passionate about helping others put their money to work. He particularly enjoys creating model portfolios that stand the test of time.

Publications where he’s appeared include InvestorPlace, The Motley Fool Canada, Investopedia, Kiplinger, and several others in both the U.S. and Canada. He lives in Halifax, Nova Scotia.

You can follow Will on LinkedIn. 

Recent Articles

10 Chinese Stocks to Buy on the Dip

ARK Invest portfolio manager Cathie Wood dumped Chinese stocks in July. Here are 10 to pick up on the dip should she decide to buy back in.

Could Nvidia Join the Trillion-Dollar Club Next Year? 

Nvidia’s market cap increased by 82% over the past year. If it keeps up, NVDA stock would hit $1 trillion by Halloween 2022. Is it doable?  

This Version of Radio Silence Is Painful for Naked Brand

Since I last wrote about Naked Brand Group in June, it has issued one news release. No news is bad news for owners of NAKD stock. 

Options Trading Does Not Make Exela Technologies a Buy

Exela Technologies announced in mid-July it was listed for options trading. If this is your best reason to own XELA stock, just stay away. 

If You Can Buy Novavax Stock at Around $200, It’s a Great Long Term Bet

Good news keeps rolling in for Novavax. However, for NVAX stock to return to $300, it needs a little help from Wall Street analysts.

United Airlines Stock Is an Opportunity for Aggressive Investors To Clean Up

The Delta variant is likely to put a scare into travelers. However, UAL stock should still do well over the next few months and into 2022.

Resist the Temptation to Buy Nio Before Earnings

Nio reports Q2 2021 results on Aug. 11 after the markets close. Only the most aggressive investors should buy NIO stock before earnings.  

7 Consumer Discretionary Stocks to Buy That Are Booking Record Profits

All kinds of companies have been reporting record profits in recent weeks. Here are seven of the best consumer discretionary stocks to buy.

Vaxart Stock Probably Isn’t Worth the Risk as It Pushes Higher

Vaxart’s oral recombinant vaccines are an interesting approach. Whether they do anything for VXRT stock remains to be seen.  

Aggressive Investors Should Avoid Clean Energy Fuels Until it Hits $5

Clean Energy Fuels is on a rollercoaster ride in 2021. Down 12.2% year-to-date, CLNE stock inches closer to penny-stock status.